Hovaguimian, Frédérique http://orcid.org/0000-0003-4181-2948
Günthard, Huldrych F. http://orcid.org/0000-0002-1142-6723
Hauser, Christoph
Conen, Anna http://orcid.org/0000-0002-5216-4109
Bernasconi, Enos http://orcid.org/0000-0002-9724-8373
Calmy, Alexandra
Cavassini, Matthias
Seneghini, Marco
Marzel, Alex
Heinrich, Henriette
Scherrer, Alexandra
Riou, Julien
Spoerri, Adrian
Schmidlin, Kurt
Balakrishna, Suraj
Braun, Dominique L.
Rampini, Silvana K. http://orcid.org/0000-0002-4788-438X
Fehr, Jan S.
Kouyos, Roger D. http://orcid.org/0000-0002-9220-8348
Aebi-Popp, K.
Anagnostopoulos, A.
Battegay, M.
Bernasconi, E.
Böni, J.
Braun, D. L.
Bucher, H. C.
Calmy, A.
Cavassini, M.
Ciuffi, A.
Dollenmaier, G.
Egger, M.
Elzi, L.
Fehr, J.
Fellay, J.
Furrer, H.
Fux, C. A.
Günthard, H. F.
Haerry, D.
Hasse, B.
Hirsch, H. H.
Hoffmann, M.
Hösli, I.
Huber, M.
Kahlert, C. R.
Kaiser, L.
Keiser, O.
Klimkait, T.
Kouyos, R. D.
Kovari, H.
Ledergerber, B.
Martinetti, G.
Martinez de Tejada, B.
Marzolini, C.
Metzner, K. J.
Müller, N.
Nicca, D.
Paioni, P.
Pantaleo, G.
Perreau, M.
Rauch, A.
Rudin, C.
Scherrer, A. U.
Schmid, P.
Speck, R.
Stöckle, M.
Tarr, P.
Trkola, A.
Vernazza, P.
Wandeler, G.
Weber, R.
Yerly, S.
,
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (177499)
Article History
Received: 25 August 2020
Accepted: 26 January 2021
First Online: 22 February 2021
Competing interests
: H.F.G. has served as a consultant or advisor to Merck & Co, Inc, ViiV Healthcare, and Gilead Sciences, Inc, as a member on data and safety monitoring boards for Merck & Co, Inc. and has received research grants from Gilead Sciences, Inc. payed to his institution. The institution of EB received fees for his participation to advisory boards and travel grants from Gilead Sciences, MSD, ViiV Healthcare, Abbvie, Pfizer, and Sandoz. D.L.B. received honoraria and travel grants unrelated to the submitted work from Merck & Co, Gilead Sciences, and ViiV Healthcare. J.S.F. received research grants unrelated to the submitted work from Merck & Co, Gilead Sciences, and ViiV Healthcare. The remaining authors declare no competing interests.